Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Operations (2023 - 2025)

Immunocore Holdings' Cash from Operations history spans 3 years, with the latest figure at 32655000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 134.07% year-over-year to 32655000.0; the TTM value through Dec 2025 reached 10712000.0, down 141.1%, while the annual FY2025 figure was 10712000.0, 141.1% down from the prior year.
  • Cash from Operations for Q4 2025 was 32655000.0 at Immunocore Holdings, down from 4456000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 25964000.0 in Q2 2025 and bottomed at 32655000.0 in Q4 2025.
  • The 3-year median for Cash from Operations is 240000.0 (2023), against an average of 1524083.33.
  • The largest YoY upside for Cash from Operations was 52060.0% in 2024 against a maximum downside of 143.52% in 2024.
  • A 3-year view of Cash from Operations shows it stood at 17733000.0 in 2023, then increased by 21.33% to 13951000.0 in 2024, then crashed by 134.07% to 32655000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Cash from Operations are 32655000.0 (Q4 2025), 4456000.0 (Q3 2025), and 25964000.0 (Q2 2025).